Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis
Journal
Therapeutic advances in chronic disease
Journal Volume
15
ISSN
2040-6223
Date Issued
2024
Author(s)
Wu, Yuan-Kun Aden
Yu, An-Li
Chou, Chia-Hung
Lin, Siao-Ping
Abstract
Transthyretin cardiomyopathy (ATTR-CM) is a debilitating disease that has received much attention since the emergence of novel treatments. The Transthyretin Cardiomyopathy Clinical Trial showed that tafamidis, a transthyretin tetramer stabilizer, effectively reduced the declines in functional capacity and quality of life. However, Ala97Ser (A97S) hereditary ATTR-CM is underrepresented in major ATTR-CM tafamidis trials.
Subjects
A97S; cardiomyopathy; speckle tracking echocardiography; tafamidis; transthyretin
SDGs
Type
journal article